ESMO 2025 Reflections

ESMO 2025 Reflections

Four potentially practice-changing bladder cancer papers This year’s ESMO congress delivered a wealth of impactful data across the bladder cancer spectrum, from muscle-invasive to metastatic disease. Here are four standout studies with potential to reshape clinical...
ESMO 2025: Ones to watch

ESMO 2025: Ones to watch

Explore the headlines set to surface at ESMO 2025. ADCs make their move into early-stage disease Drugs like Enhertu and Padcev, already headline-makers in metastatic disease, are now making waves in early-stage settings. DESTINY-Breast05, DESTINY-Breast11, and...
Spotlight on BTK Inhibitors in MS

Spotlight on BTK Inhibitors in MS

In recent years, interest in BTK inhibitors (BTKi) for MS has surged, with hopes that they could offer a new way to tackle the underlying drivers of the disease. But the journey, so far, has been a rollercoaster, and the delayed FDA decision on tolebrutinib marks the...